Evidence mapPaperPMID 37508015Full record

ReviewAntioxidants (Basel, Switzerland)2023

Complex II Biology in Aging, Health, and Disease.

Eric Goetzman, Zhenwei Gong, Bob Zhang, Radhika Muzumdar

Open access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. CoQExperimental & molecular medicine · 2026
    Review
  4. The Pro-Metastatic Roles of ROS.Antioxidants (Basel, Switzerland) · 2026
    Review
  5. Effects of Cannabidiol on TAFAZZIN-Deficient B-Lymphoblastoid Cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Mitochondrial metabolism and cancer therapeutic innovation.Signal transduction and targeted therapy · 2025
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eric GoetzmanDivision of Genetic and Genomic Medicine, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Zhenwei GongDivision of Endocrinology, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Bob ZhangDivision of Genetic and Genomic Medicine, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Radhika MuzumdarDivision of Endocrinology, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA 15260, USA.
University of Pittsburgh · US

Funding

Co-chaperone Actions in CFTR BiogenesisR01DK068196 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ERIC S GOETZMAN · 2004 to 2024
$999k
Optimizing medium-chain lipids for the treatment of long-chain fatty acid oxidation disordersR01HD103602 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2025 to 2025
$339k
NICHD NIH HHS R01 HD103602NIDDK NIH HHS R01 DK068196NIDDK NIH HHS R01 DK090242
6 · The paper itself

Abstract

Aging is associated with a decline in mitochondrial function which may contribute to age-related diseases such as neurodegeneration, cancer, and cardiovascular diseases. Recently, mitochondrial Complex II has emerged as an important player in the aging process. Mitochondrial Complex II converts succinate to fumarate and plays an essential role in both the tricarboxylic acid (TCA) cycle and the electron transport chain (ETC). The dysfunction of Complex II not only limits mitochondrial energy production; it may also promote oxidative stress, contributing, over time, to cellular damage, aging, and disease. Intriguingly, succinate, the substrate for Complex II which accumulates during mitochondrial dysfunction, has been shown to have widespread effects as a signaling molecule. Here, we review recent advances related to understanding the function of Complex II, succinate signaling, and their combined roles in aging and aging-related diseases.

Indexed as

agingComplex IIreactive oxygen speciessuccinate dehydrogenase

Identifiers

PMID37508015
PMCPMC10376733
OpenAlexW4385241049

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.